专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09868770B2 Recombinant Der P 2 expressed in Pichia Pastoris as a “natural-like” allergen for immunotherapy and diagnostic purposes 有权
公开(公告)号：US09868770B2
公开(公告)日：2018-01-16
申请号：US13109491
申请日：2011-05-17
申请人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
发明人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
IPC分类号： C07H21/02 , C07H21/04 , C12N1/00 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/04 , C12P21/06 , C07K14/435 , C12N1/16 , C12P21/00
CPC分类号： C07K14/43531 , C07H21/02 , C07H21/04 , C12N1/00 , C12N1/16 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/00
摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.

2. 发明申请

US20110293665A1 Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes 有权
标题翻译：在巴斯德毕赤酵母中表达的重组Der P 2作为免疫治疗和诊断用途的“天然样”过敏原
公开(公告)号：US20110293665A1
公开(公告)日：2011-12-01
申请号：US13109491
申请日：2011-05-17
申请人： Véronique BORDAS , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
发明人： Véronique BORDAS , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
IPC分类号： A61K39/35 , C12P21/00 , C07K14/435
CPC分类号： C07K14/43531 , C07H21/02 , C07H21/04 , C12N1/00 , C12N1/16 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/00
摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
摘要翻译：本发明涉及一种生产重组体Dermatophagoides pteronyssinus 2蛋白（rDer p2）的方法，包括以下步骤：培养先前用rDer p2编码序列转化的巴斯德毕赤酵母菌株，并从所述毕赤酵母中分离rDer p2蛋白巴斯德毕赤酵母菌株。本发明还涉及包含用于治疗或诊断用途的rDer p2蛋白的组合物和试剂盒。

3. 发明申请

US20090269363A1 METHOD FOR SCREENING PEPTIDES FOR USE IN IMMUNOTHERAPY 有权
标题翻译：筛选用于免疫缺陷病毒的方法
公开(公告)号：US20090269363A1
公开(公告)日：2009-10-29
申请号：US12186856
申请日：2008-08-06
申请人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , David Alexandre Gross
发明人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , David Alexandre Gross
IPC分类号： A61K39/00 , G01N33/567 , A61K38/00 , C07H21/02 , A61K31/7088 , A61P37/04
CPC分类号： C07K14/005 , C07K14/71 , C12N9/1241 , C12N2740/16222 , G01N33/56977
摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).
摘要翻译：鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位，来自提高细胞毒性T细胞（CTL）应答的蛋白质。（II）对应于对I类分子具有低亲和力的非免疫原性肽。制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。然后鉴定衍生活性（IIa）的肽序列。还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa）和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

4. 发明授权

US07976843B2 Method for screening peptides for use in immunotherapy 有权
标题翻译：筛选用于免疫治疗的肽的方法
公开(公告)号：US07976843B2
公开(公告)日：2011-07-12
申请号：US12186856
申请日：2008-08-06
申请人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , David Alexandre Gross
发明人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , David Alexandre Gross
IPC分类号： A61K39/00 , C07K2/00
CPC分类号： C07K14/005 , C07K14/71 , C12N9/1241 , C12N2740/16222 , G01N33/56977
摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).
摘要翻译：鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位，来自提高细胞毒性T细胞（CTL）应答的蛋白质。（II）对应于对I类分子具有低亲和力的非免疫原性肽。制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。然后鉴定衍生活性（IIa）的肽序列。还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa）和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

5. 发明授权

US07425606B2 Method for screening peptides for use in immunotherapy 有权
标题翻译：筛选用于免疫治疗的肽的方法
公开(公告)号：US07425606B2
公开(公告)日：2008-09-16
申请号：US10333430
申请日：2001-07-20
申请人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , Alexandre David Gross
发明人： Kostas Kosmatopoulos , Sophie Tourdot , Antonio Scardino , Alexandre David Gross
IPC分类号： C07K2/00
CPC分类号： C07K14/005 , C07K14/71 , C12N9/1241 , C12N2740/16222 , G01N33/56977
摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).
摘要翻译：鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位，来自提高细胞毒性T细胞（CTL）应答的蛋白质。（II）对应于对I类分子具有低亲和力的非免疫原性肽。制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。然后鉴定衍生活性（IIa）的肽序列。还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa）和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式